← Patent-cliff monitor small molecule EVRYSDI RISDIPLAM
Loss of exclusivity April 2041 latest FDA-listed patent expiry
Company Genentech → See this company's full patent-cliff portfolio Drug detail Brand name EVRYSDI Active ingredient RISDIPLAM Strength 0.75MG/ML Dosage form FOR SOLUTION Route ORAL Modality Small molecule FDA approval August 2020 Marketing status RX
Listed patents Patent Expires Type 12122789 April 2041 substance, product 11534444 October 2038 use U-1943 12350273 October 2038 use U-1943 11938136 November 2036 product 11827646 January 2036 use U-1943 9969754 May 2035 substance, product 9586955 February 2033 substance, product
Regulatory exclusivity Code Expires ODE-400 May 2029 ODE-334 August 2027 M-270 October 2026
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.